<DOC>
	<DOCNO>NCT00591253</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety azilsartan medoxomil compare placebo , daily ( QD ) , African-American participant essential hypertension .</brief_summary>
	<brief_title>Efficacy Safety Azilsartan Medoxomil African American Participants With Essential Hypertension</brief_title>
	<detailed_description>Hypertension affect approximately 50 million individual United States . As population age , prevalence hypertension continue increase broad effective preventive measure implement . According World Health Organization , hypertension common attributable cause preventable death develop nation , uncontrolled hypertension greatly increase risk cardiovascular disease , cerebrovascular disease , renal failure . Despite availability antihypertensive treatment , hypertension remain inadequately control ; one third patient continue maintain control successfully . A major component blood pressure regulation renin-angiotensin-aldosterone system , system hormone-mediated feedback interaction result relaxation constriction blood vessel response various stimulus . Angiotensin II , polypeptide hormone , form angiotensin I reaction catalyze angiotensin-converting enzyme part renin-angiotensin-aldosterone system . Angiotensin II principal pressor agent renin-angiotensin-aldosterone system myriad effect cardiovascular system electrolyte homeostasis . In United States , disproportionate number African-Americans hypertension compare age-matched non-Hispanic Caucasians Mexican Americans . Earlier onset great severity hypertension African-Americans contribute great target organ damage may factor short life expectancy population compare Caucasian-Americans . Although genetic factor invoke explain racial difference , environmental factor probably play important role . Improved management hypertension lifestyle intervention pharmacotherapy , include combination therapy , necessary achieve target blood pressure African Americans . Takeda Global Research &amp; Development Center , Inc. develop TAK-491 ( azilsartan medoxomil ) treat patient essential hypertension . Azilsartan medoxomil prodrug hydrolyze active moiety , TAK-536 ( azilsartan ) , selective antagonist angiotensin II type 1 receptor subtype . This study conduct evaluate effectiveness safety oral azilsartan medoxomil compare placebo African-American participant essential hypertension . Participation study anticipate approximately 10 week .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>1 . The participant essential hypertension ( define sit trough clinic systolic blood pressure 150 180 mm Hg , inclusive Day 1 ) 24hour mean systolic blood pressure 130170 mm Hg , inclusive , Day 1 . 2 . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . 3 . Clinical laboratory evaluation within reference range test laboratory unless result deem clinically significant inclusion study investigator . 4 . Willing discontinue current antihypertensive medication . 1 . Has sit trough clinic diastolic blood pressure great 114 mm Hg . 2 . Baseline 24 hour ambulatory blood pressure monitor read insufficient quality . 3 . Hypersensitive angiotensin II receptor blocker . 4 . History myocardial infarction , heart failure , unstable angina , coronary artery bypass graft , percutaneous coronary intervention , hypertensive encephalopathy , cerebrovascular accident , transient ischemic attack . 5 . Clinically significant cardiac conduction defect . 6 . Hemodynamically significant leave ventricular outflow obstruction due aortic valvular disease . 7 . Secondary hypertension etiology . 8 . Noncompliant study medication runin period . 9 . Severe renal dysfunction disease ( base calculate creatinine clearance le 30 mL/min/1.73 m2 ) Screening . 10 . Known suspected unilateral bilateral renal artery stenosis . 11 . History drug abuse history alcohol abuse within past 2 year . 12 . Previous history cancer remission least 5 year prior first dose study drug . 13 . Type 1 poorly control type 2 diabetes mellitus . 14 . Alanine aminotransferase level great 2.5 time upper limit normal , active liver disease , jaundice . 15 . Hyperkalemia . 16 . Upper arm circumference le 24 cm great 42 cm . 17 . Works night ( 3rd ) shift . 18 . Currently participate another investigational study participate investigational study within 30 day prior randomization . 19 . Any serious disease condition Screening ( Randomization ) would compromise participant safety , might affect life expectancy , make difficult successfully manage follow participant accord protocol . 20 . Randomized previous azilsartan medoxomil study . 21 . Is required take continue take disallow medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Blood pressure</keyword>
	<keyword>blood pressure monitoring ambulatory</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>